| MeiraGTx, J&J See Phase 3 Test Ahead for Vision Loss Gene Therapy | Sarah de Crescenzo | 07/17/20 | New York |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Bio Roundup: Moderna Publishes, Life Science Cash, AdComm Votes & More | Frank Vinluan | 07/17/20 | National |
| Adimab Spinout Adagio Raises $50M for Coronavirus Antibody R&D | Sarah de Crescenzo | 07/16/20 | Boston |
| Mallinckrodt’s Kidney Failure Drug Narrowly Wins Backing of FDA Panel | Frank Vinluan | 07/16/20 | Europe |
| Moderna Publishes Early COVID-19 Vaccine Data, Preps for Phase 3 Test | Frank Vinluan | 07/15/20 | Boston |
| Last Chance for Xconomy Awards Nominations – Deadline is Friday, July 17 | Editors | 07/15/20 | Boston |
| Dewpoint, Merck Team Up to Tackle HIV Using Condensate Know-How | Sarah de Crescenzo | 07/15/20 | Boston |
| After Biologic COVID-19 Drug OK’d in India, Equillium Plans a US Test | Sarah de Crescenzo | 07/14/20 | San Diego |
| Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact | Frank Vinluan | 07/14/20 | Boston |
| New Xconomy Podcast & Special Report Feature Boston Biophama Leaders on Digital Health | Editors | 07/14/20 | Boston |
| Amgen Doubles Down on BeiGene Collaboration, Investing $421M More | Sarah de Crescenzo | 07/13/20 | San Francisco |
| 3 Biotech IPOs Together Rake In Over a Half Billion to Advance Treatments | Sarah de Crescenzo | 07/13/20 | National |
| Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma | Sarah de Crescenzo | 07/13/20 | Boston |
| Bio Roundup: Blackstone’s Billions, Biogen Finishes Filing, Novavax at “Warp Speed” & More | Sarah de Crescenzo | 07/10/20 | National |
| Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Sarah de Crescenzo | 07/09/20 | Boston |
| NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep | Frank Vinluan | 07/09/20 | Philadelphia |
| VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | Sarah de Crescenzo | 07/09/20 | San Diego |
| Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing | Sarah de Crescenzo | 07/08/20 | Boston |
| The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period | Editors | 07/08/20 | National |
| Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck | Sarah de Crescenzo | 07/08/20 | Boston |
| Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine | Sarah de Crescenzo | 07/07/20 | National |
| Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs | Sarah de Crescenzo | 07/07/20 | Boston |
| PacBio CEO, CFO Plan Retirements and More People on the Move | Editors | 07/07/20 | National |
| On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO | Sarah de Crescenzo | 07/06/20 | San Francisco |
| Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases | Frank Vinluan | 07/06/20 | Boston |
| MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy | Sarah de Crescenzo | 07/02/20 | San Diego |
| Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients | Sarah Karlin-Smith | 07/02/20 | National |
| Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing | Frank Vinluan | 07/02/20 | San Francisco |
| Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration | Sarah de Crescenzo | 07/01/20 | San Francisco |
